[HTML][HTML] Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence …
Background Synthesising evidence on the long-term vaccine effectiveness of COVID-19
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …
COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England
The omicron (B. 1.1. 529) variant, first detected in the UK on Nov 27, 2021, rapidly became
the dominant strain, due in part to reduced vaccine effectiveness. 1 An increase in …
the dominant strain, due in part to reduced vaccine effectiveness. 1 An increase in …
Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study
R Grewal, SA Kitchen, L Nguyen, SA Buchan… - Bmj, 2022 - bmj.com
Objectives To estimate the marginal effectiveness of a fourth versus third dose and the
vaccine effectiveness of mRNA covid-19 vaccines BNT162b2 and mRNA-1273 against any …
vaccine effectiveness of mRNA covid-19 vaccines BNT162b2 and mRNA-1273 against any …
[HTML][HTML] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA. 1, BA. 2, BA. 2.12. 1, BA. 4, and BA. 5
HF Tseng, BK Ackerson, KJ Bruxvoort, LS Sy… - Nature …, 2023 - nature.com
Studies have reported reduced natural SARS-CoV-2 infection-and vaccine-induced
neutralization against omicron BA. 4/BA. 5 compared with earlier omicron subvariants. This …
neutralization against omicron BA. 4/BA. 5 compared with earlier omicron subvariants. This …
[HTML][HTML] Outcomes of elderly patients hospitalized with the SARS-CoV-2 omicron B. 1.1. 529 variant: A systematic review
RM Fericean, C Oancea, AR Reddyreddy… - International Journal of …, 2023 - mdpi.com
The Omicron (B. 1.1. 529) variant of the severe acute respiratory syndrome Coronavirus 2
(SARS-CoV-2) had an increased rate of spreading among the general population. Although …
(SARS-CoV-2) had an increased rate of spreading among the general population. Although …
[HTML][HTML] The end or a New Era of development of SARS-CoV-2 virus: Genetic variants responsible for severe COVID-19 and clinical efficacy of the most commonly …
Although the chief of the World Health Organization (WHO) has declared the end of the
coronavirus disease 2019 (COVID-19) as a global health emergency, the disease is still a …
coronavirus disease 2019 (COVID-19) as a global health emergency, the disease is still a …
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
Objective To compare the effectiveness of a primary covid-19 vaccine series plus booster
doses with a primary series alone for the prevention of hospital admission with omicron …
doses with a primary series alone for the prevention of hospital admission with omicron …
[HTML][HTML] Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection
The immunity conferred by SARS-CoV-2 vaccines and infections reduces the transmission
of the virus. To answer how the effect of immunity is shared between a reduction of …
of the virus. To answer how the effect of immunity is shared between a reduction of …
[HTML][HTML] mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
HF Tseng, BK Ackerson, LS Sy, JE Tubert… - Nature …, 2023 - nature.com
The bivalent (original and Omicron BA. 4/BA. 5) mRNA-1273 COVID-19 vaccine was
authorized to offer broader protection against COVID-19. We conducted a matched cohort …
authorized to offer broader protection against COVID-19. We conducted a matched cohort …
[HTML][HTML] Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA. 1 boosters against COVID-19 hospitalisation in England: a test …
Background Bivalent BA. 1 booster vaccines were offered to adults aged 50 years or older
and clinically vulnerable people as part of the 2022 autumn COVID-19 booster vaccination …
and clinically vulnerable people as part of the 2022 autumn COVID-19 booster vaccination …